Figures & data
Figure 1. In healthy neurons, enhancing cGMP increases cAMP and PKA presumably via cGMP-dependent inhibition of PDE3. In pro-hypertensive SHR neurons, cGMP elevation reverses the ICaN phenotype, presumably by enhancing cross-talk between cGMP and cAMP signaling via activation of PDE2A. Red arrows highlight imparied activity in pro-SHR. Yellow arrows depict the downstream effects of pharmacologically enhancing cGMP.
![Figure 1. In healthy neurons, enhancing cGMP increases cAMP and PKA presumably via cGMP-dependent inhibition of PDE3. In pro-hypertensive SHR neurons, cGMP elevation reverses the ICaN phenotype, presumably by enhancing cross-talk between cGMP and cAMP signaling via activation of PDE2A. Red arrows highlight imparied activity in pro-SHR. Yellow arrows depict the downstream effects of pharmacologically enhancing cGMP.](/cms/asset/f24a0d72-e828-403f-b62a-089fdf5d18af/kchl_a_1259040_f0001_c.gif)